105077Discovery of next generation HER2 antibodies for the treatment of cancerClosedFeasibility StudiesInnovate UKIGEM Therapeutics Ltd aims to develop a novel HER2-targeted antibody that will address a number of unmet clinical needs. It will exploit innovative animal models, novel HER2-binding antibody domains and its innovative IgE platform technology. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiated from IgG-based therapies. IGEM aims to attain a leading position in the global immune-oncology market which is forecast to reach $28 billion by 2025\.